BioAtla (NASDAQ:BCAB) & Genfit (NASDAQ:GNFT) Critical Contrast

Genfit (NASDAQ:GNFT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

2.2% of Genfit shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 11.5% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Genfit and BioAtla, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	1	0	3.00
BioAtla	0	0	2	0	3.00

Genfit currently has a consensus price target of $13.00, suggesting a potential upside of 150.00%. BioAtla has a consensus price target of $6.00, suggesting a potential upside of 159.74%. Given BioAtla’s higher probable upside, analysts clearly believe BioAtla is more favorable than Genfit.

Profitability

This table compares Genfit and BioAtla’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
BioAtla	N/A	-161.74%	-88.45%

Valuation and Earnings

This table compares Genfit and BioAtla”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$41.31 million	6.29	-$31.27 million	N/A	N/A
BioAtla	$250,000.00	446.66	-$123.46 million	($1.70)	-1.36

Genfit has higher revenue and earnings than BioAtla.

Volatility and Risk

Genfit has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.